Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1998-06-10
2001-01-09
Chin, Christopher L. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S005000, C435S007900, C435S007200, C435S069100, C349S123000, C349S124000, C349S130000, C349S137000, C530S350000, C536S023400, C536S023500
Reexamination Certificate
active
06171802
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention generally relates to the detection of a ligand by a receptor. More specifically, the present invention relates to highly specific receptors and the incorporation of these receptors into an amplification mechanism for the rapid and automatic detection of the ligand, particularly pathogens and/or their toxins.
BACKGROUND OF THE INVENTION
The detection of a ligand by a receptor (for example, detection of a pathogenic agent such as a microbe or toxin by an antibody; or detection of an antibody in blood by another antibody; or binding of a chemical toxin, such as nerve gas, to its receptor) is important in the diagnosis and treatment of individuals exposed to disease-causing agents. Early detection of pathogenic agents can be a great benefit in either disease prophylaxis or therapy before symptoms appear or worsen.
Every species, strain or toxin of a microbe contains unique surface ligands. Using molecular engineering and/or immunological techniques, receptor molecules, such as antibodies, can be isolated that will bind to these ligands with high specificity. Methods have also been developed where receptors, such as antibodies, are linked to a signaling mechanism that is activated upon binding. Heretofore, however, no system has been developed that can quickly and automatically detect and amplify a receptor signal coming from the binding of a single or a low number of ligands. Such a system is imperative for rapid and accurate early detection of ligands.
Most available diagnostic tests are antibody based, and can be used to detect either a disease-causing agent or a biologic product produced by the patient in response to the agent. There are currently three prevailing methods of antibody production for recognition of ligands (antigens): polyclonal antibody production in whole animals with recognition for multiple epitopes, monoclonal antibody production in transformed cell lines with recognition for a single epitope (after screening), and molecularly engineered phage displayed antibody production in bacteria with recognition of a single epitope (after screening). Each of these receptor systems is capable of binding and identifying a ligand, but the sensitivity of each is limited by the particular immunoassay detection system to which it is interfaced.
Immunoassays, such as enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), and radioimmunoassay (RIA), are well known for the detection of antigens. The basic principle in many of these assays is that an enzyme-, chromogen-, fluorogen-, or radionucleotide-conjugated antibody permits antigen detection upon antibody binding. In order for this interaction to be detected as a color, fluorescence or radioactivity change, significant numbers of antibodies must be bound to a correspondingly large number of antigen epitopes.
Thus, there is a need for a system that rapidly, reliably, and automatically detects ligands, especially when present in very small quantities and consequently provides a measurable signal.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to provide a system that will detect a ligand with high sensitivity and high specificity.
It is another object of the present invention to provide a system that will amplify a signal produced by the binding of a ligand to a receptor.
It is another object of the present invention to provide a caged enzyme amplification mechanism.
It is yet a further object of the present invention to provide a system that will activate an enzyme inactivated by a bound receptor.
It is still a further object of the present invention to provide a system that will distort a liquid crystal array upon the binding of a ligand to a receptor.
It is still yet a further object of the present invention to provide a detection device that will continuously monitor the environment or the body and signal its possessor when a ligand is present.
In general, the present invention provides a system for the detection and amplification of ligands, such as pathogenic agents, comprising at least one receptor and an amplification mechanism coupled to that receptor, wherein an amplified signal is produced as a result of the receptor binding the ligand.
REFERENCES:
patent: 4604364 (1986-08-01), Kosak
patent: 4943525 (1990-07-01), Dawson
patent: 5149626 (1992-09-01), Fleming
patent: 5447837 (1995-09-01), Urnovitz
patent: 5596434 (1997-01-01), Walba et al.
patent: 3617710 A1 (1986-05-01), None
Gupta, et al., Optical Amplification of Ligand-Recepter Binding Using Liquid Crystals.Sciencevol. 279 Mar. 27, 1998 pp. 2077-2079.
Harlaw and Lane,Antibodies laboratory Manual© Cold Spring Harbor Laboratory 1988 Chapter 6, pp. 141-142.
Sevier, et al., Monoclonal Antibodies in Clinical Immunology,Clinical Chemistryvol. 27 No. 11 1981 pp. 1797-1805.
R. Sutherland et al. “Surface effect immunoassay”, Stockton Press, pp. 515-542 (1991).
R. Seabrook and T. Atkinson, “Modified Antibodies”, Stockton Press, pp. 53-77 (1991).
Gupta, V.K. et al., “Design of Surfaces for Patterned Alignment of Liquid Crystals on Planar and Curved Substrates”, Science, vol. 276, pp. 1533-1536 (1997).
Abbott, Nicholas, L. et al., “Using Liquid Crystals as Probes of Nanostructured Organic Surfaces”, pp. 425-426.
Born, Max and E. Wolf. Principles of Optics, Sixth Edition, Pergamon Press, Oxford, 1980 pp. 665-703.
Deng, Su-Jun, et al. “Basis for Selection of Improved Carbohydrate-Binding Single-Chain Antibodies from Synthetic Gene Libraries.”Proc. Natl. Acad. Sci. USA. vol. 92, pp. 4992-4996, May 1995.
Griffiths, Andrew D., et al. “Human anti-self Antibodies with High Specificity from Phage Display Libraries.”The EMBO Journal. vol. 12, No. 2, pp. 725-734, 1993.
Gupta, Vinay K., et al. “Optical Amplification of Ligand-Receptor Binding Using Liquid Crystals.”Science. vol. 279, pp. 2077-2080, Mar. 27, 1998.
Holliger, Philipp. “Diabodies: Small Bivalent and Bispecific Antibody Fragments.”Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6444-6448, Jul. 1993.
Marks, James D., et al. “By-Passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage.”J. Mol. Biol., vol. 222, pp. 581-597, 1991.
Nastishin, Yu A. “Brine-Rich Corner of the Phase Diagram of the Ternary System Cetylpyridinium Chloride-Hexanol-Brine.”Langmuir, vol. 12, pp. 5011-5015, 1996.
Sanna, Pietro Paolo, et al. “Directed Selection of Recombinant Human Monoclonal Antibodies to Herpes Simplex Virus Glycoproteins from Phage Display Libraries.”Proc. Natl. Acad. Sci. USA. vol. 92, pp. 6439-6443, Jul. 1995.
Winter, Greg., et al. “Making Antibodies by Phage Display Technology.”Annul. Rev. Immunol. vol. 12, pp. 433-455, 1994.
Doane Kathleen J.
Lavrentovich Oleg
Niehaus Gary D.
Schmidt Steven P.
Signs Steven A.
Chin Christopher L.
Do Pensee T.
Kent State University
Renner Kenner Greive Bobak Taylor & Weber
LandOfFree
Detection and amplification of ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection and amplification of ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection and amplification of ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2481162